MWG Management Ltd.
Follow13F filer, CIK 1845151, Washington, DC
MWG Management Ltd. reported $91,561,604 across 3 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-08-13.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-24-008094
- Period
- 2024-06-30
- Reported value
- $91.6M
- Holdings
- 3
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| BEAMreduced | -80,000 | -$1.87M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2024
Share positions as resolved from 13F-HR 0000950123-24-008094, largest first. % of portfolio is the value over $91,561,604, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| BEAMBEAM THERAPEUTICS INC | 2,266,934 | $53.1M | 58.01% | -80,000 | Timeline | ||
| LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INC | 20,162,332 | $29.2M | 31.93% | 0 | |||
| PRMEPRIME MEDICINE INC | 1,792,210 | $9.21M | 10.06% | 0 | Timeline |
How Q2 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-24-008094 | base | 2024-08-13 | acceptance time not in the bulk data set |